m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT02108
|
[1] | |||
m6A modification
MeCP2
MeCP2
YTHDF1
 : m6A sites
Direct
Enhancement
DNA methylation
MeCP2
SLC31A1
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | YTH domain-containing family protein 1 (YTHDF1) | READER | |||
| m6A Target | Methyl-CpG-binding protein 2 (MECP2) | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | DNA methylation (DNAMeth) | ||||
| Epigenetic Regulator | Methyl-CpG-binding protein 2 (MECP2) | READER | View Details | ||
| Regulated Target | Solute carrier family 31 member 1 (SLC31A1) | View Details | |||
| Crosstalk Relationship | m6A → DNA methylation | Enhancement | |||
| Crosstalk Mechanism | m6A modification directly impacts DNA methylation through modulating the expression level of DNA methyltransferases or demethylases. | ||||
| Crosstalk Summary | YTHDF1 recognizes target Methyl-CpG-binding protein 2 (MECP2) mRNA and induces its translation. Solute carrier family 31 member 1 (SLC31A1) inhibition due to increased MeCP2-recognized methylating CpG islands of SLC31A1 in the promoter region restrains its transcription. Conversely, MeCP2 knockdown rescued SLC31A1 expression, resulting in contradictory effects. | ||||
| Responsed Disease | Vascular disorders of the liver | ICD-11: DB98.8 | |||
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
| Methyl-CpG-binding protein 2 (MECP2) | 1 Compound(s) Regulating the Target | Click to Show/Hide the Full List | ||
 Compound Name |
AVXS-201 | Phase 1 | [2] | |
|---|---|---|---|---|
| External Link | ||||